Cellular Mechanisms of Targeted Protein Degradation (TPD)
Targeted protein degradation (TPD) refers to a broad class of
therapeutic approaches that leverage cellular degradation machinery to eliminate specific
proteins. This rapidly evolving field includes diverse strategies such as molecular glues, PROTACs, lysosome-targeting chimeras (LYTACs), and antibody-based
PROTACs (AbTACs), collectively expanding the therapeutic landscape and offering new
avenues to target challenging proteins.
Figure 1. Common TPD technologies[1].
In mammalian cells, protein quality control is primarily governed by two major mechanisms: the
ubiquitin–proteasome system and the lysosomal system.
The ubiquitin–proteasome system functions as an efficient recycling
center by tagging misfolded or damaged proteins and subsequently degrading them. This process
begins with the activation of ubiquitin molecules by the E1 ubiquitin-activating enzyme, which
utilizes a small amount of ATP to prepare ubiquitin for action. Ubiquitin is then transferred to
the E2 conjugating enzyme and, with the assistance of the E3 ligase, is attached to the target
protein destined for degradation. Once the protein is tagged with a polyubiquitin chain, the 26S
proteasome recognizes and degrades these marked substrates.
The lysosomal system comprises two main pathways: the
endocytic–lysosomal pathway and the autophagic–lysosomal pathway. The endocytic–lysosomal
pathway involves the internalization of extracellular materials into vesicles, which are
subsequently delivered to lysosomes, where the acidic environment and hydrolytic enzymes degrade
the contents. The autophagic-lysosomal pathway, on the other hand, is a cellular self-digestion
process in which the cell forms a double-membraned structure known as an autophagosome to
sequester cytoplasmic components. The autophagosome then fuses with the lysosome, leading to the
degradation of its contents[1-2].
Figure 2. Two main protein quality control machinery in mammalian cells: the
ubiquitin–proteasome system and the lysosomal system[1].
Among the expanding repertoire of TPD approaches, PROTACs have emerged as a particularly
versatile strategy that leverages the ubiquitin-proteasome system
described above. Their unique capacity to catalytically degrade traditionally "undruggable"
targets underpins significant clinical potential.
To provide a comprehensive understanding, the following sections will first explore the
structural basis and design principles of PROTACs, followed by a comprehensive analysis of their
clinical applications, challenges, and future development trends.
Fundamental Principles of PROTACs
Structure and Mechanism of PROTACs
A PROTAC consists of three components: a ligand for the protein of interest
(POI), a ligand for an E3 ubiquitin ligase, and a chemical
linker connecting them. After entering the cell, the PROTAC brings the E3 ligase into
proximity with the POI by forming a ternary complex (POI-linker-E3 ligase). The E3 ligase then
mediates the transfer of ubiquitin from the E2 enzyme to the POI, marking it for degradation by
the proteasome. Owing to its catalytic nature, a single PROTAC molecule can trigger repeated
cycles of POI degradation[3].
Figure 3. Composition and mechanism of action of PROTACs.
Table 1. Comparisons of PROTACs with other therapeutic modalities[3].
Optimization Strategies for PROTAC Components
1. Selection of POI and Warhead[4]
The earliest PROTACs entering clinical trials focused on well-established classical targets.
These pioneering studies addressed critical questions regarding safety and efficacy in vivo,
demonstrating PROTACs' therapeutic potential against solid tumors. However, the most compelling
promise of PROTAC technology lies in its capacity to target "undruggable" proteins—offering a
paradigm shift from traditional small-molecule inhibition.
So far, there is no widely accepted “gold standard” for selecting PROTAC targets, similar to
Lipinski’s “rule of five” for drug-likeness. Generally, an ideal PROTAC target should:
(1) Possess disease-causing gain-of-function changes, such as overexpression, mutation, or
mislocalization;
(2) Contain a binding pocket for the PROTAC’s warhead;
(3) Have a surface site that can be ubiquitinated by an E3 ligase;
(4) Preferably include a flexible region that can be processed by the proteasome.
Importantly, high binding affinity or covalent attachment between the warhead and the POI is not
required for PROTAC activity. For instance, a study using Foretinib as a warhead showed that the
resulting PROTAC only degraded a small subset of kinases targeted by Foretinib, and degradation
efficiency was not related to binding strength. Instead, it depended on how effectively the
PROTAC formed a ternary complex with the POI and E3 ligase. In fact, very high affinity or
covalent binding can hinder PROTAC release from the complex, reducing sustained protein
degradation and making the PROTAC behave more like a traditional inhibitor.
Table 2. Reported POIs targeted by PROTACs[5].
2. Selection of E3 Ubiquitin Ligase[6]
The choice of E3 ligase can greatly influence the efficiency of targeted protein degradation.
For instance, when targeting KRAS(G12C), a PROTAC that recruited CRBN was ineffective, whereas one
recruiting VHL successfully degraded endogenous KRAS(G12C). These differences may result from
the selection of the warhead, linker, ligase, or factors such as protein size, subcellular
localization, and structural compatibility between the ligase and target.
Recent studies reveal that distinct E3 ligases generate divergent degradation
profiles—particularly for kinases—governed by three key determinants:
(1) Structural complementarity between ligase and target;
(2) Formation and cooperativity of the ternary complex, which is critical for PROTAC
activity;
(3) Subcellular localization and cell-type-specific expression of both ligase and target.
In addition to well-known ligases like CRBN, VHL, MDM2, IAPs, DCAF15, and DCAF16, other “generic” E3 ligases such as RNF4, RNF114, KEAP1, and FEM1B are emerging as promising PROTAC recruiters. Research
into their development and in vivo use is ongoing.
Advances in structural biology and AI-based protein structure prediction (e.g., AlphaFold) are
also expanding the number of ligases that can be targeted by enabling structure-based ligand
discovery.
Tissue- and cell-specific E3 ligases offer opportunities for more selective PROTAC development,
especially in tumors where certain ligases are enriched. However, challenges remain, including
ensuring druggability, understanding activation mechanisms, and developing effective screening
assays. Some ligases are auto-inhibited and require activation, which complicates their
application in PROTAC strategies.
In summary, while only a few E3 ligases are currently well-characterized for PROTAC use, ongoing
research and new technologies are rapidly expanding the available toolkit, paving the way for
more precise and effective protein degradation therapies.
Figure 4. Specialized E3 ligases for potential PROTAC applications[6].
3. Selection of Linkers[7]
Linker length typically ranges from 10 to 20 atoms. Recent analyses show a characteristic
L-shaped relationship between normalized degradation activity and linker length. Long linkers
diminish degradation potency due to entropic effects, while short linkers cause steric clashes,
also leading to a sharp drop in potency. Therefore, PROTAC design often starts with a slightly
longer linker, followed by iterative length optimization. Not only is the interaction between
the PROTAC molecule and the binding pocket of the target protein affected by the linker length,
but the overall physicochemical properties of the PROTAC molecule are also impacted by linker
length and structural composition.
Table 3. Different linker motifs and their features[8].
Clinical Landscape, Challenges, and Future Directions of PROTACs
Clinical Development of PROTACs
The therapeutic potential of PROTACs is rapidly translating into the clinic, with multiple
candidates currently in clinical trials targeting cancers, autoimmune disorders, and
neurodegenerative diseases. Most utilize oral delivery and CRBN-based E3 recruitment.
Table 4. Representative PROTACs in clinical trials[9-10].
“/”means undisclosed.
Advantages and Challenges of PROTACs
Table 5. Summary of key advantages and challenges of PROTACs[11].
Challenges——The Hook Effect in PROTACs
PROTAC-mediated ternary complex formation follows a bell-shaped concentration-response curve due
to the “hook effect” – at elevated concentrations (1-10 μM), nonproductive binary complexes
(PROTAC-POI or PROTAC-E3 ligase) outcompete functional ternary complexes (POI-PROTAC-E3 ligase),
reducing degradation efficacy. Recent studies demonstrate that enhancing positive cooperativity
in protein-protein interactions (PPIs) can mitigate this phenomenon. The BTK-targeting PROTAC
MT-802 exhibited no observable hook effect below 2.5 μM through optimized ternary complex
stabilization. Notably, macrocyclization emerged as an innovative strategy to enforce
cooperative binding by conformationally constraining PROTACs, energetically favoring productive
ternary complexes over binary counterparts. Compared to linear analog MZ1, macrocyclic PROTACs
demonstrated superior degradation potency and target selectivity. These insights underscore the
importance of ternary complex recognition principles for structure-guided PROTAC design,
warranting advanced structural and biophysical studies to unravel the intricate molecular
recognition mechanisms underlying this process
[13-14].
Figure 5. Dose-dependent degradation of hCAII by Degrader 4 and 5[14].
In concentrations above their maximum activity, both compounds exhibited a well-known
attenuation in target degradation known as the “hook effect”.
Summary
PROteolysis TArgeting Chimeras (PROTACs) represent a transformative approach in targeted protein
degradation (TPD), leveraging the cell’s own ubiquitin–proteasome system to selectively
eliminate disease-associated proteins. Unlike traditional small-molecule inhibitors, PROTACs can
degrade both the enzymatic and non-enzymatic functions of protein targets, including those
previously considered “undruggable.” The modular design of PROTACs—comprising a ligand for the
protein of interest, a ligand for an E3 ubiquitin ligase, and a linker—allows for the catalytic
and reversible removal of pathogenic proteins. Recent advances have expanded the repertoire of
E3 ligases and linker chemistries, enabling broader therapeutic applications and improved
selectivity. Several PROTACs are in clinical development, targeting diverse diseases such as
cancer, neurodegeneration, and immune disorders. Despite their promise, challenges remain,
including the identification of suitable target ligands, limited diversity of E3 ligases,
mechanistic gaps in rational design, and the need for dedicated PK/PD evaluation systems.
Additionally, the “hook effect” and the distinction between PROTAC and molecular glue mechanisms
require further investigation. Nevertheless, PROTACs offer a powerful platform to overcome drug
resistance and expand the therapeutic frontier for previously inaccessible protein targets.
MCE is a globally leading supplier of research chemicals and biochemical reagents, equipped with
a strong technical team and state-of-the-art facilities. We have extensive experience in the
research, development, and production of PROTAC-related
products. Currently, over 3,700 PROTAC-related products are available in our catalog, with
the number continually increasing.
For PROTAC research, MCE provides one-stop services, including the design, synthesis, purification,
analysis, optimization, and evaluation of PROTAC-related molecules (e.g., ligands for E3
ligases, PROTAC linkers, ligands for target proteins, conjugates, PROTACs, SNIPERs, and
PROTAC-linker conjugates for PAC).
For target proteins with unknown ligands, we also offer a wide range of compound libraries and virtual
screening resources to facilitate ligand discovery and PROTAC construction. Additionally,
we provide comprehensive characterization data—including structure, physicochemical properties,
and impurity profiles—for all customized products to ensure quality and consistency.
Figure 6. PROTAC-related products and services offered by MCE.
Instagram
